Izinketho Zokwelapha Umdlavuza Wamaphaphu Amancane 2026: I-ADC Entsha & Ukuphumelela Kwe-Immunotherapy 

Izinketho ezincane zokwelapha umdlavuza wamaphaphu ngo-2026 ziye zavela ngokuphawulekayo, zasuka ezinhlotsheni zemithi yokwelapha ngamakhemikhali kuphela zaya ekuhlanganiseni okuthuthukisiwe okuhlanganisa i-immunotherapy, ama-antibody-drug conjugates (ADCs), kanye nezihlanganisi ze-T-cell ezihlosiwe. Izindinganiso zamanje zihlanganisa i-chemotherapy esekelwe ku-platinum ehlanganiswe ne-PD-L1 inhibitors yokunakekelwa komugqa wokuqala, kuyilapho ukuphumelela okusha okufana nemithi yokwelapha eqondiswe yi-DLL3 kanye nama-ADC anama-antibody amabili achaza kabusha imiphumela yokusinda kuzo zombili izifo zesigaba esilinganiselwe kanye nesigaba esikhulu.

Ukuqonda Isimo Sendawo Yamanje Yezinketho Zokwelashwa Komdlavuza Wamaphaphu Amaseli Amancane

Umdlavuza wamaphaphu omncane (SCLC) usalokhu ungenye yezinhlobo ezinonya kakhulu zobubi, obonakala ngokukhula ngokushesha kanye nokumetastasis kwasekuqaleni. Ngokomlando, izinketho zokwelashwa komdlavuza wamaphaphu amancane zazilinganiselwe kumakhemikhali amakhemikhali e-platinum-etoposide, ayenikeza amazinga aphezulu okusabela okuqala kodwa ukuphila okungekuhle isikhathi eside. Ukusinda okuphelele okumaphakathi kwe-SCLC yesigaba esibanzi (ES-SCLC) akuvamile ukuba kudlule unyaka owodwa.

Kodwa-ke, indawo yokwelapha iye yaba noshintsho lwepharadigm. Ukuhlanganiswa kwama-immune checkpoint inhibitors kumaphrothokholi omugqa wokuqala sekuphenduke indinganiso entsha yomhlaba wonke. Ngaphezu kwalokho, u-2026 uphawula unyaka obalulekile lapho izindlela zenoveli, okuhlanganisa i-bispecific T-cell engagers kanye nama-ADC esizukulwane esilandelayo, zisuka ezigabeni zokuhlola ziye eqinisweni lasemtholampilo. Le ntuthuko ibhekana nesidingo esibalulekile sokwelashwa okuphumelelayo komugqa wesibili kanye nomugqa wesithathu, indawo elokhu imile amashumi eminyaka.

Ukuhlukaniswa kwe-SCLC ku-Limited-Stage (LS-SCLC) kanye ne-Extensive-Stage (ES-SCLC) kuyaqhubeka nokubeka isu lokwelapha eliyinhloko. I-LS-SCLC ingase yelapheke nge-chemoradiotherapy kanyekanye elandelwa yi-consolidation immunotherapy. Ngokuphambene, i-ES-SCLC iphethwe njengesimo esingamahlalakhona, egxile ekwandiseni isikhathi sokusinda nokugcina izinga lempilo ngokwelashwa okuhlelekile. Ukuqonda lokhu kwehluka kubalulekile ezigulini nakubanakekeli abazulazula ngenqwaba yezinto ezitholakalayo izinketho zokwelashwa komdlavuza wamaphaphu amancane.

Iqhaza Lokuthayipha Ngama-Molecular Ekwelapheni Kwesimanje

Ucwaningo lwakamuva luye lwagqamisa ukuhlukahluka kwe-SCLC, okuholela ekuhlonzweni kwama-subtypes amangqamuzana asekelwe ekuvezweni kwezici ezibalulekile zokuloba ezifana ne-ASCL1, NEUROD1, POU2F3, ne-YAP1. Lokhu kuhlukaniswa akuseyona nje eyemfundo; isiqala ukuba nomthelela ekwakhekeni kwesilingo somtholampilo kanye nezindlela zokwelashwa eziqondene nawe. Isibonelo, ama-subtypes athile angase aphendule kangcono kuma-immunotherapies athile noma ama-ejenti ahlosiwe afana nama-DLL3 inhibitors.

Nakuba ukuhlolwa kwendawo yonke yalezi zinhlobo ezincane kungakabi yinjwayelo kuyo yonke imitholampilo, ukuqaphela lokhu kwehlukahlukana kwezinto eziphilayo kusiza ukuchaza ukuthi kungani ezinye iziguli zisabele kahle ngendlela engavamile ekwelashweni kwamasosha omzimba kuyilapho ezinye zingakwenzi lokho. Njengoba sidlulela ku-2026, okulindelekile ukuthi iphrofayela yamangqamuzana izoba yingxenye evamile yokugeleza komsebenzi wokuxilonga, kuqhubeke kucwengisise ukukhethwa izinketho zokwelashwa komdlavuza wamaphaphu amancane.

Amazinga Womugqa Wokuqala: Inhlanganisela ye-Immunotherapy

Isisekelo sokwelashwa kwesimanje komugqa wokuqala womdlavuza wamaphaphu omncane wesigaba esibanzi inhlanganisela yokwelapha ngamakhemikhali okusekelwe ku-platinum kanye ne-immune checkpoint inhibitor. Le ndlela ibonise inzuzo yokusinda engashintshi kuzo zonke izivivinyo eziningi ezinkulu zeSigaba sesi-III, isungula ibhentshimakhi entsha yokunakekelwa.

Lo mshini uhlanganisa ukusebenzisa i-chemotherapy ukuze kubangele ukufa kwamaseli e-immunogenic, "i-priming" ye-tumor microenvironment. I-immunotherapy eyengeziwe, ngokuvamile i-PD-L1 noma i-PD-1 inhibitor, ivimbela ukungasebenzi kwama-T-cell, okuvumela amasosha omzimba ukuthi aqhubeke nokuhlaselwa kwamangqamuzana omdlavuza. Le synergy iguqule ukubikezelwa kweziguli eziningi.

• I-Atezolizumab: Ngokusekelwe ocwaningweni lwe-IMpower133, i-atezolizumab ehlanganiswe ne-carboplatin ne-etoposide kwaba uhlobo lokuqala olubonisa inzuzo enkulu yokusinda iyonke. Idatha yokulandelela yesikhathi eside eyethulwa ngo-2026 iqinisekisa ukusinda okuhlala isikhathi eside, ne-subset yeziguli ezisinda ngaphezu kweminyaka emihlanu.
• I-Durvalumab: Uhlolo lwe-CASPIAN lusungule i-durvalumab kanye ne-platinum-etoposide njengenye inketho eqinile. Izibuyekezo zakamuva zigqamisa iphrofayili yayo yokuphepha evumayo kanye nokuvumelana nezimo ekuhleleni, okuyenza ibe inketho ekhethwayo ezinhlelweni eziningi zokunakekelwa kwezempilo.
• I-Serplulimab: Idatha evelayo iphakamisa ukuthi i-serplulimab, inoveli ye-PD-1 inhibitor, inikeza ukusebenza ngempumelelo okunamandla. Ucwaningo olwethulwa ezingqungqutheleni ezinkulu ze-oncology ngo-2026 lukhombisa imiphumela ethembisayo uma isetshenziswa kuhlanganiswe nokwelashwa ngamakhemikhali, ikakhulukazi ekubalweni kwabantu abathile beziguli.
• I-Adebrelimab: Lokhu kusungulwa kwasekhaya kubonise imiphumela emangalisayo ezifundweni ezinkulu. Ukubuyekezwa kwesikhathi eside kocwaningo lwe-CAPSTONE-1 kuveza ukuthuthuka okubalulekile ekusindeni okuphelele okumaphakathi, okuqinisa inani lama-ejenti ahlukahlukene we-immunotherapy endaweni yokwelapha.

I-Consolidation Therapy Yezifo Ezisezingeni Elilinganiselwe

Ezigulini ezinesigaba esilinganiselwe, inhloso yokwelashwa iyelapha. Izinga lokunakekelwa libandakanya i-chemoradiotherapy (cCRT). Impumelelo enkulu eminyakeni yamuva nje ukwamukelwa kwe-consolidation immunotherapy kulandela i-cCRT.

Isilingo se-ADRIATIC siguqule igeyimu kulesi silungiselelo. Kubonise ukuthi ukuphatha i-durvalumab njengokwelashwa kokuhlanganiswa ngemva kwe-cCRT ephumelelayo kwandisa kakhulu kokubili ukusinda okungenanqubekela phambili kanye nokusinda okuphelele. Lokhu okutholakele kuholele ekugunyazweni kokulawula kanye nezibuyekezo zemihlahlandlela, okwenza ukuhlanganiswa kwe-immunotherapy kube ukucatshangelwa okuyimpoqo ezigulini ezifanelekile ze-LS-SCLC.

Ukwengeza, uphenyo ngamashejuli we-hypofractionated radiotherapy kuhlanganiswe ne-immunotherapy luyaqhubeka. Imiphumela yasekuqaleni iphakamisa ukuthi ukushintsha amaphethini emithamo yemitha kungase kuthuthukise ukuphendula kwamasosha omzimba, okungase kuthuthukise imiphumela ngokuqhubekayo. Lawa masu athuthukayo amele unqenqema lwe izinketho zokwelashwa komdlavuza wamaphaphu amancane ngezifo zasendaweni.

Ukunyuka Kwama-Antibody-Drug Conjugates (ADCs)

Ama-Antibody-Drug Conjugates (ADCs) amele isigaba soguquko se izinketho zokwelashwa komdlavuza wamaphaphu amancane. Ngokungafani nokwelashwa ngamakhemikhali okungokwesiko, okuthinta wonke amaseli ahlukana ngokushesha, ama-ADC asebenza “njengemicibisholo eqondiswayo.” Aqukethe i-antibody eqondise iphrotheni ethile endaweni yeseli yomdlavuza, exhunywe kumthwalo okhokhelwayo we-cytotoxic. Uma i-antibody ibophezela kulokho okuhlosiwe, inkimbinkimbi ifakwa ngaphakathi, futhi umthwalo okhokhelwayo ukhishwa ngokuqondile ngaphakathi kweseli lesimila, kuncishiswe ukulimala kwezicubu ezinempilo.

Ngo-2026, ama-ADCs azuza amandla hhayi nje njengemithi yomugqa wesibili kuphela kodwa futhi ngokuhambisana nokwelashwa kwamasosha omzimba ngokwelashwa komugqa wokuqala. Le ndlela ekabili iphakamisa ukunemba kwe-ADC namandla esistimu okusebenza kokuzivikela komzimba.

I-B7-H3 Ama-ADC Ahlosiwe: I-Ifinatamab Deruxtecan

Enye yentuthuko ejabulisa kakhulu ukuvela kwama-ADC ahlosiwe e-B7-H3, afana ne-finatamab deruxtecan (I-DXd). I-B7-H3 iyiphrotheni evezwa kakhulu kumaseli e-SCLC kodwa anomkhawulo ezicutshini ezivamile, okuyenza ibe inhloso ekahle.

Imininingwane yomtholampilo eyethulwe kamuva nje ibonisa isithembiso esimangalisayo. Ezigulini ezine-SCLC yesigaba esikhulu eziye zathuthuka ngemva kokwelashwa kwangaphambili, i-I-DXd ibonise izinga lokuphendula elihlosiwe elidlula i-50% kanye nezinga lokulawula izifo ezingaphezu kuka-90%. Mhlawumbe ngokubucayi kakhulu, le ejenti ibonise ikhono lokuwela umgoqo wegazi-ubuchopho.

Ama-metastases obuchopho ayinkinga evamile futhi ebhubhisayo ye-SCLC. Imithi yokwelapha yendabuko ivame ukuhluleka ukungena esimisweni sezinzwa esimaphakathi ngokuphumelelayo. Ikhono le-I-DXd lokunciphisa izimila ezise-intracranial linikeza indlela yokuphila ezigulini ebezinezinketho ezimbalwa kakhulu ngaphambilini. Izinhlolo eziqhubekayo zeSigaba sesi-III ziqhathanisa le ejenti ngokumelene nokwelashwa ngamakhemikhali okujwayelekile, okulindelwe imiphumela okungenzeka ichaze kabusha izinga lomugqa wesibili lokunakekelwa.

I-Dual-Targeting ADCs: Iza-bren (BL-B01D1)

Omunye umngcele ukuthuthukiswa kwama-ADC ama-bispecific. I-Iza-bren (BL-B01D1) iyi-EGFR×HER3 eqondiswe kabili kabili i-ADC. Nakuba i-EGFR ne-HER3 kuvame ukuhlotshaniswa nomdlavuza wamaphaphu ongewona omncane, ukuvezwa kwabo ku-SCLC kanye nendlela eyingqayizivele yalo muthi kuveze imiphumela emangalisayo.

Izifundo zakamuva zeSigaba II ezihlanganisa i-iza-bren ne-serplulimab zibike amamethrikhi okusinda angakaze abonwe ngaphambili. Idatha ikhombisa izinga lokusinda lonyaka owodwa lifinyelela ku-86%, inani elenza lisebenze kahle kakhulu izilinganiso zomlando zesifo sesigaba esikhulu. Lo mshini ubonakala ungahlanganisi nje ukubulawa kwamangqamuzana okuqondile kodwa futhi nokuguqulwa kwezimila “ezibandayo” (ezingasebenzi ngokuzivikela komzimba) zibe izimila “ezishisayo,” ngaleyo ndlela kuthuthukiswe ukusebenza kahle kwe-immunotherapy ngesikhathi esifanayo.

Lo mphumela we-synergistic ugqamisa ithrendi ebalulekile ngo-2026: ukuya kumithi yokwelapha eyinhlanganisela ephusile. Ngokumatanisa i-ADC eyenza ukufa kwe-immunogenic cell nge-checkpoint inhibitor ekhulula amabhuleki amasosha omzimba, odokotela bathola izimpendulo ezijulile nezihlala isikhathi eside. Lezi zindlela ezintsha zandisa umkhathi wokusebenza izinketho zokwelashwa komdlavuza wamaphaphu amancane.

Iqondise i-DLL3: Inkathi Entsha Yomuthi Onembile

I-Delta-like ligand 3 (DLL3) iyiphrotheni engaphezulu etholakala kuningi lamangqamuzana omdlavuza wamaphaphu wamangqamuzana amancane kodwa cishe ayikho ezicutshini ezivamile zabantu abadala. Lokhu kuyenza ithagethi ephelele yokwelashwa okunembayo. Sekuyiminyaka, ukukhomba i-DLL3 kube nzima, kodwa u-2026 ubone ukuvuthwa kwezindlela ezimbili ezihlukene: I-Bispecific T-cell Engagers (BiTEs) kanye neRadioligand Therapies.

I-Tarlatamab: I-Bispecific T-cell Engager

I-Tarlatamab iyi-bispecific T-cell engageer exhumanisa ama-T-cell esiguli namaseli omdlavuza aveza i-DLL3. Ngokuvala leli gebe, kuphoqa amasosha omzimba ukuthi ahlasele isimila kungakhathaliseki ukuthi ama-T-cell azowubona ngokwemvelo umdlavuza.

Ukugunyazwa okusheshisiwe nezinhlelo zokufinyelela ezandisiwe zenze i-tarlatamab yatholakala ezigulini ezine-SCLC ebuyele emuva noma ephikisayo. Izivivinyo zemitholampilo zibonise amazinga okuphendula okuhlosiwe phakathi kuka-40% no-55% kubantu abalashwe kakhulu, inani labantu ngokuvamile elibona amazinga okuphendula angaphansi kuka-10% ngokwelashwa ngamakhemikhali okujwayelekile.

Nokho, ukusetshenziswa kwe-tarlatamab kudinga ukuphathwa ngokucophelela. Ukusebenza okunamandla kwama-T-cell kungaholela ku-Cytokine Release Syndrome (CRS), impendulo yokuvuvukala kwesistimu. Ukwengeza, idatha yomhlaba wangempela igqamise izingozi ezithile ze-pneumonia ne-nephritis. Odokotela manje basebenzisa amasu okudosa okwenyusa kanye nezinqubo zokuqapha ngokuqinile ukuze banciphise lezi zingozi, baqinisekise ukuthi izinzuzo ezijulile zalokhu kwelashwa zingatholakala ngokuphepha.

I-Radioligand Therapy Targeting DLL3

Ngaphandle kokusebenzelana kwamaselula, i-DLL3 iphinde iqondiswe ngokwelashwa kwe-radioligand. Le ndlela ihlanganisa ukunamathisela i-isotope ekhipha imisebe ku-antibody noma i-peptide ebophezela ku-DLL3. Imisebe ihanjiswa ngqo endaweni yesimila, isindise izitho ezizungezile ezinempilo.

Izivivinyo zesigaba sokuqala ziphakamisa ukuthi le ndlela ingase isebenze ikakhulukazi ezigulini ezinesifo se-metastatic esandile, kuhlanganise nalabo abathintekayo amathambo nobuchopho. Ikhono lokuletha umthamo ophezulu wemisebe ngendlela ehlelekile ngaphandle kobuthi bemisebe ye-beam yangaphandle kuyinzuzo ephoqelelayo. Nakuba kusaphenywa kakhulu ngo-2026, lokhu kumelela ikusasa inketho yokwelashwa komdlavuza wamaphaphu amancane okungase kusheshe kungene umkhuba ojwayelekile.

Ukuhlaziywa Okuqhathanisayo Kwemithi Yokwelapha Esafufusa

Ngokutheleka kwemithi emisha, ukukhetha indlela efanele kungaba yinkimbinkimbi. Ithebula elilandelayo liqhathanisa ukhiye ovelayo izinketho zokwelashwa komdlavuza wamaphaphu amancane okuxoxiwe ngakho, kugqanyiswe izindlela zabo, isimo samanje, kanye namacala okusetshenziswa afanelekile.

Lesi siqhathaniso sigcizelela ukuhlukahluka kwendawo yokwelapha. Lapho kwake kwaba khona indlela eyodwa, manje sekunezindlela eziningi ezenzelwe izigaba ezahlukene zesifo nezici zebhayoloji. Ukukhethwa kokwelashwa kuya ngokuya ngokuya kuncike ekwelashweni kwangaphambili, isimo sokusebenza, namaphrofayili athile e-biomarker.

Ukuphatha imiphumela emibi kanye namaphrofayili okuphepha

Njengoba izinketho zokwelashwa komdlavuza wamaphaphu amancane babe namandla kakhulu, ukuphatha imiphumela yabo emibi kubaluleka ngokulinganayo. Isigaba ngasinye somuthi siveza iphrofayili yobuthi eyingqayizivele edinga ukuphathwa okusebenzayo.

Izehlakalo Ezibi Ezihlobene Ne-Immunotherapy (irAEs)

Ama-immune checkpoint inhibitors angabangela ukuvuvukala kunoma yiluphi uhlelo lwesitho. Ama-IRAE ajwayelekile afaka i-dermatitis, i-colitis, i-hepatitis, kanye ne-endocrinopathies njengokungasebenzi kahle kwe-thyroid. Kuyathakazelisa ukuthi enye idatha iphakamisa ukuthi iziguli ezithola i-IRAE emnene zingase zibe nezimpendulo ezingcono zesimila, okubonisa ukusebenza okuqinile kokuzivikela komzimba.

Ukuphatha ngokuvamile kuhilela i-corticosteroids nokumiswa okwesikhashana komuthi. Ukutholwa kusenesikhathi kubalulekile. Iziguli zifundiswa ukubika izimpawu ezinjengokukhwehlela okuqhubekayo, isifo sohudo, noma ukukhathala ngokushesha. Ngokuqapha okufanele, ama-IRAE amaningi ayahlehliswa futhi ayalawuleka.

Ubuthi Be-ADC-Specific

Ama-ADC aletha ezawo izinselelo. I-Interstitial Lung Disease (ILD) noma i-pneumonitis ingozi eyaziwayo enemithwalo ethile ekhokhelwayo, ikakhulukazi ama-agent asekelwe e-deruxtecan. Ukuhlolwa kwezithombe okujwayelekile nokusebenza kwamaphaphu kugunyazwe ngesikhathi sokwelashwa. Ukwengeza, ubuthi be-hematological obufana ne-neutropenia ne-thrombocytopenia buvamile ngenxa yemvelo ye-cytotoxic yomthwalo okhokhelwayo.

Isicanucanu, ukukhathala, kanye ne-alopecia nakho kuyavama kodwa kuyalawuleka ngokunakekelwa okusekelayo. Iwindi lokwelapha lama-ADC lincane, lidinga umthamo oqondile kanye nokubhekwa okuqaphile yithimba lezokwelapha.

I-Tarlatamab kanye ne-CRS Management

Ukusetshenziswa kwe-tarlatamab kudinga izivumelwano ezikhethekile zokusingatha i-Cytokine Release Syndrome. Izimpawu zisukela kumkhuhlane omncane kuye ku-hypotension enkulu kanye nokungasebenzi kahle kwezitho zomzimba. Ukwenyusa umthamo, lapho imithamo yokuqala iphansi ukuze ijwayelane kancane kancane namasosha omzimba, kubonakale kusebenza ngempumelelo ekwehliseni ubukhali be-CRS.

Ngaphezu kwalokho, ingozi ye-pneumonia ne-nephritis ehlonzwe ekuhlaziyweni komhlaba wangempela idinga ukuthi odokotela baqaphe ngokuseduze ukusebenza kokuphefumula nezinso. Naphezu kwalezi zingozi, amandla okukhululwa okuhlala isikhathi eside ezimweni eziphikisayo enza lezi zindlela zokwelapha zibe isengezo esibalulekile ku-toolkit ye-oncologist.

Izinyathelo Ezisebenzayo Zeziguli Nabanakekeli

Ukuzulazula emhlabeni oyinkimbinkimbi wokwelashwa kwe-SCLC kungaba nzima. Nansi inkomba esebenzayo yokusiza iziguli kanye nemindeni ukuthi bahlanganyele ngempumelelo nabahlinzeki bazo bezempilo mayelana izinketho zokwelashwa komdlavuza wamaphaphu amancane.

• Isinyathelo 1: Qinisekisa Isiteji kanye Nohlobo Oluncane: Qinisekisa ukuthi ukulinganisa okunembile (okulinganiselwe uma kuqhathaniswa nokubanzi) kusungulwa nge-imaging ebanzi (CT, MRI, PET). Buza mayelana ne-molecular subtyping uma itholakala, njengoba ingase ibe nomthelela ekufanelekeleni ukuhlolwa komtholampilo.
• Isinyathelo sesi-2: Xoxa Ngesu Lomugqa Wokuqala: Ngesifo sesigaba esibanzi, qinisekisa ukuthi uhlelo luhlanganisa ukwelashwa ngamakhemikhali kanye ne-immune checkpoint inhibitor. Ngesigaba esilinganiselwe, buza mayelana nomugqa wesikhathi wokuhlanganiswa kwe-immunotherapy ngemuva kwe-chemoradiation.
• Isinyathelo sesi-3: Hlola Izivivinyo Zomtholampilo: Uma ubheka ukuvela kwemvelo okusheshayo kwenkambu, buza ngokuqondile mayelana nezilingo ezibandakanya ama-ADC noma ama-DLL3 amakhambi ahlosiwe. Izindlela eziningi zokwelapha eziphumelelayo zifinyeleleka kuphela ngalezi zinhlelo.
• Isinyathelo sesi-4: Hlela ukuqapha: Misa uhlelo lokuskena okujwayelekile nomsebenzi wegazi. Qonda izimpawu zemiphumela engemihle engaba khona njenge-pneumonia noma i-CRS futhi wazi ukuthi kufanele ufune nini ukunakekelwa okuphuthumayo.
• Isinyathelo sesi-5: Cabangela Ukunakekela Okusekelayo: Hlanganisa ukunakekelwa kwe-palliative kusenesikhathi. Lokhu akusho ukuyeka; kunalokho, igxile ekulawulweni kwezimpawu kanye nezinga lempilo, elinganweba ngempela ukusinda lapho kuhlanganiswa nokwelashwa okusebenzayo.

Ukuba ngummeli onolwazi kubalulekile. Indawo ye izinketho zokwelashwa komdlavuza wamaphaphu amancane kushintsha ngokushesha kunangaphambili, futhi ukubamba iqhaza ngenkuthalo ekuthathweni kwezinqumo kungaholela emiphumeleni engcono.

Izikhombisi-ndlela zesikhathi esizayo kanye ne-Horizons yocwaningo

Umfutho ocwaningweni lwe-SCLC awubonisi zimpawu zokunensa. Ngaphandle kwezindlela zokwelapha ezisakhula kamuva, kubhekwa izindlela ezimbalwa ezithembisayo. Indawo eyodwa enentshisekelo enkulu inhlanganisela yama-ejenti anoveli amaningi, njengokumatanisa i-DLL3-targeted BiTE ne-ADC, noma ukuhlanganisa ama-immunomodulators amathathu ahlukene.

Omunye umngcele ukusetshenziswa kobuhlakani bokwenziwa ukubikezela impendulo yokwelashwa. Ngokuhlaziya amasethi edatha amaningi olwazi lwe-genomic nolwazi lomtholampilo, amamodeli e-AI angakwazi ukuncoma ngokushesha izinketho zokwelashwa komdlavuza wamaphaphu amancane kweziguli ngazinye ezinokunemba okuphezulu.

Ngaphezu kwalokho, umqondo "wokwelapha okusebenzayo" uyakhula. Njengoba abasindile besikhathi eside sebevame kakhulu ngenxa yokwelashwa kwamasosha omzimba kanye nama-ejenti aqondiwe abasafufusa, umgomo usuka ekwandiseni impilo nje uye ekuzuzeni ukuxolelwa okuhlala isikhathi eside, okungenakwelashwa. Ucwaningo lwamasu okunakekela kanye nezinqubo zokunciphisa izinga labaphenduli besikhathi eside luyaqhubeka.

Imithi yokugoma eqondise kuma-antigen athile e-SCLC nayo isathuthuka. Le mithi yokugoma yokwelapha ihlose ukuqeqesha amasosha omzimba ukuze abone futhi abhubhise amangqamuzana omdlavuza ngokuqhubekayo, okungenzeka avimbele ukuphindeka ngemva kwempumelelo yokwelashwa kwasekuqaleni.

Isiphetho: Ukusa Okusha Kokunakekelwa kwe-SCLC

Unyaka ka-2026 umi njengomzuzu obalulekile emlandweni womdlavuza omncane wamaphaphu. Ushintsho olusuka kumbono ongekho emthethweni luye kwelethemba langempela luqhutshwa ukuqina kwesayensi nokucabanga okusha. Ukuhlanganiswa kwe-immunotherapy ezingeni lokunakekelwa kwakuyisiqalo nje. Namuhla, ukuvela kwama-antibody-drug conjugates afana ne-finatamab deruxtecan kanye ne-iza-bren, eduze nokunemba kwezindlela zokwelapha eziqondiswe ku-DLL3 njenge-tarlatamab, kunikeza amathuba angakaze abonwe.

Iziguli ezitholwe zine-SCLC namuhla zinokufinyelela kuhlu olubanzi, oluyinkimbinkimbi kakhulu izinketho zokwelashwa komdlavuza wamaphaphu amancane kunanini ngaphambili. Nakuba izinselele zisekhona, ikakhulukazi ekulawuleni ubuthi kanye nokunqoba ukumelana, umzila uphezulu ngokusobala. Ukusebenzisana phakathi kwabacwaningi, odokotela, kanye neziguli kuqhuba inguquko eguqula isifo esake saba yingozi saba isimo esilawulekayo, futhi eseselapheka ngezikhathi ezithile.

Njengoba sibheke esikhathini esizayo, ukugxila kusala ekwenzeni kube ngokwakho kanye nokunemba. Konke okusha okutholakele kusisondeza emgomweni wokugcina: ukuqeda umdlavuza wamaphaphu wamangqamuzana amancane. Okwamanje, umyalezo ucacile—kunethemba, kukhona ongakhetha kukho, futhi ukulwa kusekude ukuphela.